

PRESS RELEASE

Piramal Critical Care Expands Generic Injectables Portfolio with U.S. Launch of New Concentration of Zinc Sulfate for Injection, USP

Bethlehem, PA – January 16, 2024: Piramal Critical Care (PCC), a division of Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635), announces the launch of a new 10mg/10mL (1 mg/mL) concentration of Zinc Sulfate for Injection USP in the U.S. The launch will enable PCC to further expand their existing Zinc Sulfate Injection product line and overall the generic injectables portfolio.

Zinc Sulfate is a trace element indicated in adult and pediatric patients as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. This intravenous nutritional injection is available in three strengths: 30mg/10mL (3mg/mL), 25mg/5mL (5mg/mL), and the new 10mg/10mL (1mg/mL) concentration. The 1 mg/mL concentration is recommended for use in pediatric patients, particularly those weighing less than 26 pounds. [Full prescribing information available here.](#)



Peter DeYoung, Chief Executive Officer of Piramal Global Pharma commented: “Piramal Critical Care (PCC) is excited to introduce the latest addition to our lineup: the 10mg/10mL (1 mg/mL) concentration of Zinc Sulfate for Injection. This launch aligns with our core mission of supplying the market with medications that play a crucial role in saving and enhancing patients' lives. The introduction of Zinc Sulfate Injection expands our US portfolio of injectable products, complementing our already market-leading inhaled anesthesia offerings. Our commitment to delivering critical care solutions remains steadfast as we aim to serve patients and healthcare providers, in the U.S. and globally.”

The launch of Zinc Sulfate for Injection, USP 10mg/10ml is the latest in a series of recent product launches from Piramal Critical Care in the generic injectables market. In 2023, Piramal Critical Care also announced launches of Pantoprazole Sodium for Injection, USP and Doxycycline for Injection, USP to further complement their wide portfolio of critical care products.

About Piramal Critical Care:

Piramal Critical Care (PCC) is a global leader in anesthesia, pain management, and intrathecal therapy. Piramal Critical Care maintains a wide global footprint, delivering continuous supply to hospitals in more than 100 countries around the world. Their product portfolio includes inhaled anesthetics, intrathecal treatments for spasticity and pain management, plasma volume expanders, and a variety of other injectables and generics. Piramal Critical Care has strong manufacturing and process development capabilities with state-of-the-art manufacturing facilities in Bethlehem, PA, United States, Digwal, India, and Dahej, India with global regulatory accreditations and adherence to strict GMP regulations. In addition, Piramal Critical Care partners with leading pharmaceutical development and manufacturing organizations around the world.

Piramal Critical Care, Inc.

3950 Schelden Circle, Bethlehem, Pennsylvania 18017-8936
Telephone: 610-974-9760 Fax: 610-861-4746
piramalcriticalcare.com

For more information visit <http://www.PiramalCriticalCare.us> | [LinkedIn](#)

About Piramal Pharma Ltd.:

Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter products. In addition, one of PPL's associate companies, AbbVie Therapeutics India Private Limited (formerly Allergan India Pvt Ltd), a joint venture between Allergan (now part of AbbVie) and PPL, has emerged as one of the market leaders in the ophthalmology therapy area. Further, PPL has a minority investment in Yapan Bio Private Limited. In October 2020, PPL received a 20% strategic growth investment from the Carlyle Group.

For more information visit: <http://www.piramal.com/pharma> | [LinkedIn](#) | [Twitter](#)

For Media Queries:

Rajiv Banerjee
Group Head - Corporate Communications
rajiv.banerjee@piramal.com

For Investors:

Gagan Borana
General Manager - Investor Relations & Sustainability
gagan.borana@piramal.com